

抗PCSK9抗体薬はLDLコレステロール低下に有効である

GAUSS-2: スタチン不耐性の難治性患者に対しEvolocumabはエゼチミブよりも有効である

GAUSS-2: Evolocumab superior to ezetimibe for clinically challenging statin-intolerant patients

低密度リポ蛋白コレステロール (LDL-C) を低下させるPCSK9阻害薬と呼ばれるある種の注射剤evolocumabは、スタチン内服不能患者において副作用がほとんどなくエゼチミブよりも有効であるとのGAUSS-2の結果が第63回American College of Cardiology学会で発表され、*Journal of the American College of Cardiology*オンライン版に掲載された。GAUSS-2スタディでは、307人の患者(平均年齢62歳、女性46%)が2つのevolocumab療法群(140mgを2週間毎または420mgを月1回に加えプラセボを毎日内服)または2つのエゼチミブ療法群(プラセボ注射を2週間毎または月1回に加えエゼチミブ10mgを毎日内服)のいずれかにランダムに割り付けられた。LDL-Cのベースラインからの低下である一次エンドポイントは合致した: evolocumab治療群において第12週のLDL-Cのベースラインからの低下が53~56%であったのに対し、エゼチミブ治療群では37~39%。筋骨格系の副作用はevolocumab使用患者の12%において報告されたのに対し、エゼチミブでは23%であった。治療関連副作用がevolocumab群の8%、およびエゼチミブ群の13%に認められたため、試験は中止された。

Full Text

Evolocumab, an injected form of a class of drugs called PCSK9 inhibitors that lower low-density lipoprotein cholesterol (LDL-C) outperformed ezetimibe with few side effects in patients unable to take statins, according to research from GAUSS-2 presented at the American College of Cardiology's 63rd Annual Scientific Session and published online in the *Journal of the American College of Cardiology*.

High LDL cholesterol is considered a major risk factor for cardiovascular disease. Statins are commonly prescribed to reduce that risk. Currently ezetimibe is one of the few options to lower LDL-C for patients who cannot tolerate statins, but it is less effective than statins in decreasing LDL-C.

GAUSS-2 is a 14-country, 12-week double-blind comparison of subcutaneously administered evolocumab versus oral ezetimibe in patients with high cholesterol who were unable to tolerate effective doses of at least two different statins. In this phase III study, half of patients tried three statins unsuccessfully, and 22 percent couldn't tolerate any of at least four different statin drugs. The patients had a minimum LDL-C level of 193 mg/dL.

A total of 307 patients were randomly assigned to one of two evolocumab regimens (140 mg every two weeks or 420 mg per month, plus daily placebo) or one of two ezetimibe groups (a placebo injection every two weeks or monthly, plus 10 mg oral ezetimibe daily). Mean age was 62 years, and 46 percent of patients were women.

The primary endpoints of LDL-C reductions from baseline were met: 53 percent to 56 percent decrease of LDL-C from baseline at week 12 in evolocumab-treated patients, corresponding to a 37 percent to 39 percent LDL-C decrease with ezetimibe. Musculoskeletal side effects were reported in 12 percent of patients on evolocumab compared to 23 percent on ezetimibe. More than 94 percent of all enrolled patients completed the study. The study drug was stopped because of treatment-related side effects in 8 percent of evolocumab patients and 13 percent of ezetimibe patients. Safety data for evolocumab versus ezetimibe include the following side effects: headache (8 percent vs. 9 percent), muscle pain (8 percent vs. 18 percent), pain in extremities (7 percent vs. 1 percent), muscle spasms (6 percent vs. 4 percent), fatigue (4 percent vs. 10 percent), nausea (4 percent vs. 7 percent), diarrhea (2 percent vs. 7 percent), sensation of tingling, pricking or burning known as paresthesia (1 percent vs. 5 percent). Patients who were taking low-dose statins were more likely to develop muscle pain in both study arms than those who took no statins (evolocumab, 17 percent vs. 6 percent; ezetimibe, 21 percent vs. 17 percent).

"We have a growing population of patients treated with at least two different types of statins who still experience side effects so much they want to discontinue the drug," said Erik S.G. Stroes, M.D., chair and professor at the Department of Vascular Medicine in Amsterdam's Medical Center and the study's principal investigator. "The one big difference between our study and others in patients at increased cardiovascular risk is that for these patients, we don't have a good alternative treatment – no drug with robust LDL-lowering potency and good tolerability. For clinicians trained to solve problems, an unmet clinical need is a big issue."

Earlier studies indicate that more than 75 percent of patients who failed one statin can still do well on a second statin drug. This finding makes patients who have been unable to tolerate two or more statins a particularly challenging group.

Stroes noted that clinicians have debated whether cardiovascular patients would accept a drug administered by injection, but the study's cardiovascular physicians and internists found few problems with the subcutaneous regimen. Evolocumab must be delivered by this route because it's a fully human monoclonal antibody, a protein that will be broken down in the stomach and bowel if taken orally.

"What's innovative here is that if you give a drug, it's hardly ever specific; statins, for example, can work on a lot of organs," Stroes said. "An antibody is, in and of itself, inert. It binds selectively to a particular sequence on a protein or bacteria and can have a predictable effect on a particular system. That's most likely why evolocumab has a good safety profile with very high efficacy. This study suggests that statin-induced myopathy may be due to another molecular pathway and is not related to LDL-C lowering per se."

There is no generally accepted definition of statin intolerance yet, Stroes said. The GAUSS-3 study, planned to start in the second half of 2014, will include a separate placebo-controlled re-exposure to statin before evolocumab therapy.

"It will help in further delineating statin intolerance and how that should be defined in clinical practice," he said.

Stroes noted two limitations to the study. Reducing LDL-C levels has been demonstrated to translate into a reduced risk of cardiovascular events primarily with statin treatment. The benefit of evolocumab on cardiovascular endpoints awaits the results of the ongoing FOURIER trial. Additionally, the 12-week duration of this study was rather short considering that the majority of patients require life-long treatment to manage LDL-C. The good tolerability observed in this study also needs confirmation in the ongoing long-term trials, Stroes said.

The GAUSS-2 trial was funded by Amgen, Inc.

ACC2014特集

[News01]

セリアック病は冠動脈疾患リスクを上昇させる

[News02]

宇宙において宇宙飛行士の心臓はより球状になる

[News03]

スタチンは勃起不全の症状を改善する

[News04]

出産した子供の数は女性の将来の心血管系の健康状態に影響する

[News05]

腎除神経術は治療抵抗性高血圧に有益性をもたらさない

[News06]

クロニジンは相殺による有益性はもたらさずリスクを上昇させる

[News07]

非心臓手術周術期のアスピリン使用は重大な出血を増加させる

[News08]

糖尿病管理目的の肥満手術の持続的効果

[News09]

血液バイオマーカーがMI否定に有望であることが示された

[News10]

自己拡張型TAVRを用いた際の死亡は手術と比較が少ない

[News11]

STEMIにおいてペバリンはbivalirudinよりも優れている

[News12]

モノクローナル抗体阻害とスタチンの組み合わせのLDL-Cに関する評価

[News13]

抗PCSK9抗体薬はLDLコレステロール低下に有効である

[News14]

ステント留置後抗凝固療法個別化によりMIおよび死亡リスクが低下した

[News15]

ビタミンD欠乏はより重篤な疾患と関連する

[News16]

心臓再同期療法は心不全の生存率を改善する